cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Yolanda Handayani
Contact Email
yola.aksel@gmail.com
Phone
+6282157048069
Journal Mail Official
respirologyscience@gmail.com
Editorial Address
Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Location
Kota adm. jakarta timur,
Dki jakarta
INDONESIA
Respiratory Science
Published by Perhimpunan Dokter Paru Indonesia
ISSN : -     EISSN : 24741306     DOI : https://doi.org/10.36497/respirsci.v1i3.17
Core Subject : Health,
Health Professions Medicine & Pharmacology
Focuses on original article reviews and case reports in pulmonary and critical care medicine Scope: 1. Asthma 2. Chronic Obstructive Pulmonary Disease (COPD) 3. Lung Physiology and Sleep-Related Disorder 4. Lung Infection 5. Thoracic Oncology 6. Interstitial Lung Disease 7. Environmental Lung Disease 8. Tobacco Control 9. Occupational Pulmonary Disease 10. Pulmonary Intervention and Emergency Medicine 11. Respiratory critical care 12. Respiratory immunology and biomolecular
Arjuna Subject : Kedokteran - Kedokteran Paru dan Pernafasan
Articles 6 Documents
 1 
Search results for , issue "Vol. 2 No. 2 (2022): Respiratory Science" : 6 Documents clear
Vitamin C Supplementation Improves Pulmonary Tuberculosis Patients' Sputum Conversion During Intensive Phase Category I Treatment in Medan Elok Ariyani Safitri; Parluhutan Siagian; Bintang Yinke Magdalena Sinaga; Putri Chairani Eyanoer
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.30

Abstract

Background: Many factors influence the success of the acceleration of Acid-Fast Bacilli (AFB) sputum conversion in the treatment of the intensive phase of pulmonary tuberculosis (TB). One of these factors is the nutritional status or nutrition of pulmonary TB patients. Through a fenton reaction, Vitamin C is known to be able to sterilize Mycobacterium tuberculosis. This study aims to determine the effect of giving vitamin C on the conversion of AFB sputum in the intensive phase of pulmonary TB treatment. Method: This study was an inferential, quasi-experimental evaluation of the acceleration of AFB sputum conversion following vitamin C supplementation in patients with category I pulmonary TB. The study group was separated into two groups: 40 TB patients getting Anti Tuberculosis Treatment (ATT) with vitamin C, and 40 TB patients receiving ATT with placebo. Every two weeks, AFB sputum was examined, and vitamin C levels were measured before and after two months of therapy. Results: Conversion of AFB occurred sooner in the vitamin C group of pulmonary TB patients, with as many as 29 patients (72.5%) experiencing conversion of AFB sputum at the end of the second week of therapy, whereas there was no conversion in the placebo group. At the end of the fourth week, all patients (100%) given vitamin C showed AFB sputum conversion, whereas only eight patients (20%) in the placebo group had conversion at the end of the fourth week of treatment. Vitamin C levels increased significantly in the group of pulmonary tuberculosis patients who received vitamin C supplementation. Conclusion: Vitamin C supplementation in the treatment of pulmonary TB can accelerate the conversion of AFB sputum, which is statistically significant.
The Association of Acquired Resistance EGFR Exon 20 T790M Mutation and Treatment Response in Lung Adenocarcinoma Patients Receiving EGFR-TKI: Relationship between Acquired Resistance T790M Mutation and RECIST 1.1 Muhammad Harbi Praditya; Noni Novisari Soeroso; Setia Putra Tarigan; Taufik Ashar
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.32

Abstract

Background: Lung adenocarcinoma patients receiving EGFR-TKI may develop acquired resistance within 7-16 months of treatment initiation, which is characterized by the presence of exon 20 T790M mutations in treatment response patients and can be assessed objectively by CECT and then evaluated by RECIST 1.1. The purpose of this study is to look into the association between acquired resistance EGFR Exon 20 T790M mutation and treatment response in lung adenocarcinoma patients receiving EGFR-TKI. Method: This research is an analytic study with a retrospective cohort design carried out at the Oncology Polyclinic at Haji Adam Malik Hospital from October 2020 to January 2021 in all patients with adenocarcinoma lung cancer who were treated with EGFR-TKI for more than 6 months. After that, an evaluation was carried out based on RECIST 1.1 and then examined for EGFR mutations from liquid biopsy specimens in the form of circulating tumor plasma DNA (ct-DNA) with the droplet digital Polymerase Chain Reaction (ddPCR) method to detect EGFR exon 20 T790M mutations as a marker of acquired resistance. Results: It was found that the majority of subjects were female (64.5%), aged 20-69 years (58%), and non-smokers (67.7%). The most common EGFR mutation was exon 19 deletion (58.1%). The incidence of acquired resistance was found in 10 subjects (32.3%). The distribution of RECIST 1.1 results on positive acquired resistance includes progressive diseases of 35.2%; stable disease of 11.1%; partial response of 33.4%; and 100% complete response. Negative acquired resistance includes 64.8% progressive disease, 88.9% stable disease, 66.6% partial response, and 0% complete response (P=0.93). Conclusion: There is no significant association between the incidence of acquired resistance mutations EGFR exon 20 T790M and treatment response in patients with lung adenocarcinoma who received EGFR-TKI therapy.
Air Pollution and Respiratory Diseases During The Hajj Season in The Holy City of Makkah Mukhtar Ikhsan
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.37

Abstract

The holy city of Makkah is one of the big cities in Saudi Arabia that is densely populated, especially during the Hajj season. In recent years, air pollution in Makkah has been a growing problem due to construction activities, motor vehicle fumes, rising temperatures, rainfall and humidity. The higher the level of air pollution exposure, the more it has an impact on human health, especially the lungs and airways. The health impacts associated with air pollution include an increase in the incidence of respiratory infections, asthma, chronic obstructive pulmonary disease and other lung diseases. Better knowledge of the correlation between air pollution and lung and airway diseases will contribute to developing more strategies to reduce air pollution in the holy city of Makkah.
Neutrophyl – Lymphocyte Ratio (NLR) and C-Reactive Protein (CRP) Levels in Stable and Exacerbated Chronic Obstructive Pulmonary Disease (COPD) Patients in Persahabatan Hospital Jakarta Astari Pranindya Sari; Ratnawati Ratnawati; Wahju Aniwidyaningsih; Sita Laksmi Andarini; Faisal Yunus
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.38

Abstract

Background: Although COPD has been believed to be characterized by respiratory disease, there are currently limited study conducted to evaluate inflammation markers and exacerbation rate in COPD by noninvasive methods. We did a prospective cohort study to observe the alteration of Neutrophyl-Lymphocyte Ratio (NLR) and C-reactive protein (CRP) in COPD patients to find any possible correlation with COPD exacerbation status. Method: From July to December 2018, a prospective cohort study was performed with blood and spirometry test on 31 COPD patients during exacerbation (AE-COPD) and stable. The mean of NLR and CRP were compared and analyzed. Results: Both NLR and CRP decreased during stable condition (from 7.95±6.8 to 4.6±5.5 and 43.4±71 to 12.2±18.5) with P<0.01 respectively. We also found a significant inverse correlation between NLR and FEV1/FVC in AE-COPD and CRP showed an inverse correlation only with FEV1 in AE-COPD. Another interesting finding was a subject with very high CRP whose value remained above the nomal limit during stable, and died within 2 months after exacerbation. Conclusion: NLR and CRP levels in COPD patients increased during exacerbation, which may reflect lung function and exacerbation status.
Chemotherapy in Lung Cancer With Hepatic and Renal Impairment Aida Hastuti; Erna Kusumawardhani; Haryati Haryati
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.42

Abstract

Chemotherapy is one of the therapeutic modalities for lung cancer. Chemotherapy with anticancer drugs has a narrow therapeutic index and pharmacokinetic variability between individuals. The administration of anticancer drugs should consider many factors that may affect the pharmacokinetics of the drug, such as hepatic and renal function. In lung cancer patients who have hepatic and renal impairment, an adjusted dose of anticancer drug is needed to achieve levels of drug exposure similar to patients who have normal organ function and avoid toxicity. Renal function is calculated by the glomerular filtration rate or creatinine clearance. Assessment of hepatic function can be taken from Child Pugh's score or from bilirubin and aminotransferase enzyme data in patients. In addition, hepatitis screening is also required. The results of the assessment will determine the adjustment dose recommendation for anticancer drugs.
Multiple Possible Causes Of Dyspnea In An Unusual Pickwickian Syndrome On Covid-19 Pandemic: A Case Study Steven Jonathan; Menaldi Rasmin
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.44

Abstract

Introduction: Pickwickian Syndrome (PS) or obesity hypoventilation syndrome (OHS) is a diagnosis of exclusion with features of obesity, sleep disordered breathing, and chronic daytime hypercapnia. Patients with PS could present into general OSA or respiratory failure. We are presenting an unusual case of PS with acute respiratory failure resulting in organ failure and mortality. Case report: A 41-year-old male was admitted to hospital due to shortness of breath. He had a trouble sleeping; frequently awoke as the breathing briefly stopped and gasping. There were history of diabetes melitus (DM) and hypertension for >10 years, smoking with moderate Brinkman Index. Patient appeared to have somnolence, tachypnea, hypoxemia, morbid obesity. We assessed him as PS, bronchopneumonia, respiratory failure, pulmonary edema, hypertensive heart disease (HHD), DM, acute on CKD. We managed him with pharmacotherapy, oxygen (BiPAP), and hemodialysis. After transferred from ICU to regular ward, patient was suddenly apneic and CPR was performed; ended in mortality. Discussion: This unusual case (malignant OHS) was a subgroup among OHS with greater morbidity and multiorgan system dysfunction. There were multiple causes of dyspnea on our patient which concluded to a death case. There are three modalities of management in stable PS: positive airway pressure (PAP), weight reduction, and pharmacotherapy. The management of respiratory failure in PS mainly involved oxygen therapy in positive pressure. Conclusion: There were multiple causes of dyspnea in this patient. Optimal management of patient ought to treat not only the PS but also all the comorbidities.

Page 1 of 1 | Total Record : 6

 1 

Filter by Year

2022 2022


Reset
Filter By Issues
All Issue Vol. 2 No. 3 (2022): Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science Vol. 2 No. 1 (2021): Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science Vol. 1 No. 2 (2021): Respiratory Science Vol. 1 No. 1 (2020): Respiratory Science